Last reviewed · How we verify

NCT03960242: PARK001

Evaluation of Clinical Progression in Patients With Motor Predominant Parkinson Disease.

Terminated Last updated 21 December 2022
What this trial tests

trial in Parkinson Disease in 3 participants. Terminated before completion.

Timeline
14 January 2019
Primary endpoint
18 April 2021
18 April 2021

Quick facts

Lead sponsorBrainEver
StatusTerminated
Study typeOBSERVATIONAL
Enrollment3
Start date14 January 2019
Primary completion18 April 2021
Estimated completion18 April 2021
Sites2 locations across France

Conditions studied

Sponsor

BrainEver

Who can join

Under 70, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is the longitudinal prospective clinical evaluation in patients with motor predominant PD; it will assess the individual disease progression (change) of the clinical and imaging parameters measured at 6-month interval over a minimum of 12 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03960242.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing